Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms

J Med Chem. 2012 Apr 26;55(8):3595-613. doi: 10.1021/jm200990c. Epub 2012 Feb 15.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / chemical synthesis*
  • Anti-HIV Agents / chemistry
  • Anti-HIV Agents / pharmacokinetics
  • Anti-HIV Agents / pharmacology
  • Benzodiazepines / chemistry
  • Binding Sites
  • Crystallography, X-Ray
  • Drug Design*
  • HIV Reverse Transcriptase / antagonists & inhibitors*
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Hydrogen Bonding
  • Imidazoles / chemistry
  • Indoles / chemistry
  • Nitriles / chemistry
  • Reverse Transcriptase Inhibitors / chemical synthesis*
  • Reverse Transcriptase Inhibitors / chemistry
  • Reverse Transcriptase Inhibitors / pharmacokinetics
  • Reverse Transcriptase Inhibitors / pharmacology
  • Structure-Activity Relationship

Substances

  • 4,5,6,7-tetrahydroimidazo-(4,5,1- jk)(1,4)benzodiazepin-2 (1 H)-one
  • Anti-HIV Agents
  • Imidazoles
  • Indoles
  • Nitriles
  • Reverse Transcriptase Inhibitors
  • Benzodiazepines
  • reverse transcriptase, Human immunodeficiency virus 1
  • HIV Reverse Transcriptase